Jingtao Zhong

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 5

Top Topics

Monoclonal Antibody

Radiation Therapy

Top Venues

Nature communications

Oxidative medicine and cellular longevity

This page only lists publications with an associated author ORCID identifier.

Publications

Zhongchao Li, Jing Liu, Bo Zhang, Jinbo Yue, Xuetao Shi, Kai Cui, Zhaogang Liu, Zhibin Chang, Zhicheng Sun, Ming-Ming Li, Yue Yang, Zhao Ma, Lei Li, Chengsheng Zhang, Pengfei Sun, Jingtao Zhong, Lei Zhao
Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial. Nature communications 15 (1) (2024)
Zhongchao Li, Jing Liu, Bo Zhang, Jinbo Yue, Xuetao Shi, Kai Cui, Zhaogang Liu, Zhibin Chang, Zhicheng Sun, Ming-Ming Li, Yue Yang, Zhao Ma, Lei Li, Chengsheng Zhang, Pengfei Sun, Jingtao Zhong, Lei Zhao
Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial. Nature communications 15 (1) (2024)
Zhongchao Li, Jing Liu, Bo Zhang, Jinbo Yue, Xuetao Shi, Kai Cui, Zhaogang Liu, Zhibin Chang, Zhicheng Sun, Ming-Ming Li, Yue Yang, Zhao Ma, Lei Li, Chengsheng Zhang, Pengfei Sun, Jingtao Zhong, Lei Zhao
Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial. Nature communications 15 (1) (2024)
Zhongchao Li, Jing Liu, Bo Zhang, Jinbo Yue, Xuetao Shi, Kai Cui, Zhaogang Liu, Zhibin Chang, Zhicheng Sun, Ming-Ming Li, Yue Yang, Zhao Ma, Lei Li, Chengsheng Zhang, Pengfei Sun, Jingtao Zhong, Lei Zhao
Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial. Nature communications 15 (1) (2024)
Yinghong Zhou, Xiaofeng Dong, Peng Xiu, Xin Wang, Jianrong Yang, Lei Li, Zhongchao Li, Pengfei Sun, Xuetao Shi, Jingtao Zhong
Meloxicam, a Selective COX-2 Inhibitor, Mediates Hypoxia-Inducible Factor- (HIF-) 1α Signaling in Hepatocellular Carcinoma. Oxidative medicine and cellular longevity 2020 (2020)